Introduction {#s1}
============

Metastasis is a multi-step process that begins with migration of cancer cells from the primary tumor into the circulation to reach lymph nodes and the parenchyma of distant organs ([@bib52]; [@bib43]). In host organs, disseminated cancer cells interact with a tissue microenvironment that includes organ-specific resident cells, immune cells, perivascular niches, extracellular matrix, cytokines, metabolites, and an oxygen concentration range. This environment eliminates the majority of cancer cells that infiltrate the parenchyma from the circulation, and selects for cells that can adapt, survive as latent entities, and form micrometastases that may eventually grow into clinically manifest metastases. The progression from micro- to macrometastasis is thought to entail a dynamic interaction between disseminated cancer cells and the host microenvironment, which determines an organ-specific pattern of metastatic relapse characteristic of each type of cancer ([@bib62]; [@bib12]).

Overt metastasis is associated with high morbidity and mortality, and is a major clinical concern. Large metastatic lesions accumulate genetic and epigenetic alterations and stably express specific transcriptional signatures ([@bib21]; [@bib69]). In recent years, analysis of these signatures in cells derived from human tumors and xenografts has uncovered numerous factors whose expression mediates organ-specific metastasis in animal models and is associated with organ-specific metastasis in patients ([@bib22]; [@bib41]; [@bib57]; [@bib8]; [@bib7]; [@bib77]; [@bib79]; [@bib14]; [@bib72]; [@bib9]; [@bib26]). Some of these mediators serve as targets of therapeutic intervention against metastatic cancer ([@bib12]; [@bib74]). By contrast, cancer cells in the early stages of metastatic colonization may dynamically alter their gene expression profiles in response to specific stresses experienced in distant organs as they adapt to the host tissue microenvironment and form long-lasting metastatic seeds. These early disseminated cells represent a crucial transition state and may be particularly vulnerable to therapy since they can sometimes be eliminated using adjuvant therapy after surgical resection of primary tumors, unlike established macrometastases. Thus, it is critical to understand the vulnerabilities, dynamic as they may be, of early micrometastases. However, insight into the dynamic early micrometastatic state has been limited by the lack of sensitive techniques for in situ transcriptomic analysis of minute numbers of disseminated cancer cells within large host organs.

Current techniques to study cell-type-specific transcriptomes have limitations that preclude their effective application in studying metastasis-initiating cancer cell populations. Single-cell RNA sequencing (scRNA-seq), with or without an intervening fluorescence activated cell sorting (FACS) step, allows identification of the transcriptomes of underrepresented cell populations at a single-cell level, but it requires extensive physical and enzymatic processing of the tissue, which disrupts the effects of the host microenvironment while exerting stress on these cells, thus compromising the ability to discern the impact of the host stroma from the transcriptome of the isolated cells. Furthermore, only about 10--20% of the transcripts are captured during the library preparation in scRNA-seq which severely limits the coverage of transcriptome of cells of interest ([@bib36]). In addition, scRNA-seq is challenging to apply in tissues and cell types that are difficult to dissociate into single cells. In situ transcriptomic profiling obviate these problems but lack the necessary sensitivity for disseminated cancer cells that represent less than 1% of the tissue cell population. For example, translating ribosome affinity purification and mRNA sequencing (TRAP-Seq) ([@bib34]) is not suitable to analyze cells that constitute less than 1% of the total population ([@bib6]; [@bib61]). Direct-enzyme-based metabolic tagging of RNA with thiouracil (TU) and ethynyl cytosine (EC) in the cells of interest are limited in sensitivity and specificity due to collateral tagging and purification of tagged RNA in cells lacking the enzymes, and requires additional in vitro biotinylation steps ([@bib16]; [@bib28]; [@bib27]; [@bib56]; [@bib35]). TU tagging has a sensitivity limit of 5% ([@bib27]). Thiol (SH)-linked alkylation of the metabolic labeling of RNA in tissue (SLAM-ITseq) eliminates the noise associated with the purification of RNAs that are not thiol tagged in TU-tagging method ([@bib53]), but undesired TU tagging through endogenous enzymes in cells lacking UPRT expression remains a limitation. Other methods such as laser capture microdissection/RNA-seq are useful in preserving the spatial information ([@bib60]), however, require sophisticated tools and are challenging to use in rare cell populations that are sparsely distributed in the tissue.

Here, we describe the development of a CD-based method for in situ transcriptomic profiling of rare cell populations with high sensitivity (less than 0.01% of an organ), and the application of this method to the analysis of organ-specific micrometastatic adaptation. Using this approach, we define microenvironment-dependent transcriptional programs in micrometastatic pulmonary and brain metastases from breast cancer, identify oxidative stress as a lung-specific liability of disseminated cancer cells, and demonstrate that NRF2 activation and upregulation of distinct antioxidant genes are adaptive responses to this stress in lung micrometastases. This oxidative stress and adaptive transcriptional events are reversible upon removal of metastatic cells from the tissue microenvironment, and disappear when metastasis-derived cells are placed in culture. We validate our findings in metastatic tumors from different organ sites from patients with breast cancer. Thus, Flura-seq identifies both a dynamically induced organ-specific stress program activated by metastasis-initiating cancer cells in the pulmonary microenvironment, as well as an adaptive transcriptional program that ensures cancer cell survival, which could be targeted to therapeutic advantage.

Results {#s2}
=======

5-FU tagging allows isolation and quantitation of variable abundance transcripts {#s2-1}
--------------------------------------------------------------------------------

Cytosine deaminase (CD) is a key enzyme of the pyrimidine salvage pathway in fungi and prokaryotes, but is absent in mammalian cells, which instead use cytidine deaminase for the same purpose ([@bib58]). In addition to converting cytosine to uracil, CD can also convert 5-fluorocytosine (5-FC), a non-natural pyrimidine, to 5-fluorouracil (5-FU). 5-FU is endogenously converted to fluorouridine triphosphate (F-UTP), which is incorporated into RNA ([Figure 1A,B](#fig1){ref-type="fig"}). An antibody-based purification step that specifically captures the 5-FU-tagged RNA would yield a sample suitable for sequencing. Although 5-FU or the combination of CD expression and 5-FC treatment are cytotoxic in some cells ([@bib4]; [@bib42]; [@bib47]), such toxicity requires more than 7 days of treatment ([@bib32]; [@bib40]). We hypothesized that short-term 5-FC treatment in CD-expressing cells may avert such toxic effects and minimize transcriptional distortion, thus allowing in situ transcriptomic profiling of rare cell populations.

![Cell-type-specific labeling and isolation of RNAs by Flura-tagging.\
(**A**) Schematic diagram showing RNA labeling and isolation using CD and 5-FC; (**B**) Chemical reactions steps involved in the labeling of RNA using CD and 5-FC; (**C**) Enrichment of mRNAs immunopurified by anti-BrdU antibody in cells expressing CD relative to WT cells and normalized to their corresponding inputs after 5-FC treatment for the indicated times, as measured by qRT-PCR for the representative genes (*n* = 3,±S.E.); (**D**) Schematic diagram of the constructs used for inducible expression of UPRT and/or CD, and the experimental design of Flura-tagging; (**E**) MDA231 cells expressing RFP-IRES-CD or UPRT-T2A-RFP-IRES-CD were co-cultured with unmodified control cells, treated with 5-FC, and Flura-tagging was assessed by BrdU immunostaining (*n* = 3, Scale bar, 20 μM). Arrow indicates cells lacking CD expression but stained with BrdU antibody; (**F**) 100, 500 or 1000 human MDA231 cells expressing CD/UPRT were co-cultured with 10^6^ mouse 4T1 cells, treated with 5-FC for 12 hr, and 5-FU-tagged RNAs were immunoprecipitated. The fold enrichment of the indicated representative human genes over mouse housekeeping genes (*mHPRT1*) was measured by qRT-PCR (*n* = 3 ± S.E.). p*-*Values were calculated by unpaired two-tailed student's t test.](elife-43627-fig1){#fig1}

We expressed *S. cerevisiae* CD in human embryonic kidney 293 T cells (293 T-CD cells), and treated the cells with 5-FC to yield intracellular 5-FU, which is incorporated into newly synthesized RNA. Antibodies against bromodeoxyuridine (BrdU) crossreact with other halogenated uridines incorporated into nucleic acids ([@bib3]). Accordingly, untransfected control cells incubated with 5-FU showed positive anti-BrdU immunofluorescence, whereas cells incubated with 5-FC did not ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). The anti-BrdU antibody also stained 293 T-CD cells when treated with 5-FC, demonstrating that the antibody binds to exogenous or CD-generated 5-FU derivatives but not 5-FC derivatives ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). To test the specificity and efficiency of RNA isolation, we immunoprecipitated messenger RNA (mRNA) from 5-FU-labeled cells with the anti-BrdU antibody and determined the mRNA levels of representative high expression genes (*glyceraldehyde 3-phosphate dehydrogenase, GAPDH; tubulin beta chain, TUBB*) and low expression genes (*chemokine CX3C motif ligand 1, CXC3L1*) by reverse transcriptase-polymerase chain reaction (RT-PCR). In 293 T-CD cells, these mRNAs were detectable after 2 hr of treatment with 5-FC, and the levels continued to increase for up to 24 hr ([Figure 1C](#fig1){ref-type="fig"}). The relative enrichment of the RNAs was two to three orders of magnitude higher in 293 T-CD cells compared to control 293 T cells ([Figure 1C](#fig1){ref-type="fig"}). These results demonstrate that 5-FU tagging allows specific labeling and purification of newly synthesized transcripts.

Cell specificity of RNA Flura-tagging {#s2-2}
-------------------------------------

5-FU can be transported across cell membranes based on its concentration gradient ([@bib63]; [@bib81]). Therefore, we determined whether 5-FU labeling of RNAs using this method would be restricted to CD-expressing cells or collaterally affect neighboring cells. We generated CD-expressing derivatives of MDA-MB-231 (MDA231) cells, a cell line derived from the pleural fluid of a patient with highly metastatic, triple hormone receptor-negative breast cancer ([@bib11]). The CD-expressing derivative cells, MDA231-CD, were co-cultured with unmodified MDA231 cells ([Figure 1D](#fig1){ref-type="fig"}), incubated with 5-FC, and the 5-FU labeling of individual cells was determined based on anti-BrdU immunofluorescence. The co-cultures showed 5-FU-labeling not only in MDA231-CD cells but also in unmodified MDA231 cells ([Figure 1E](#fig1){ref-type="fig"}).

To limit the diffusion of 5-FU from CD-expressing cells, we implemented a dual strategy. First, we engineered MDA231 cells to co-express CD and uracil phosphoribosyl transferase (UPRT). UPRT directly converts 5-FU to 5-fluorouridine monophosphate (F-UMP), which does not diffuse across cell membranes, bypassing the generation of 5-fluorouridine ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). We developed a polycistronic vector that allows doxycycline (Dox)-inducible co-expression of UPRT, CD and red fluorescence protein (RFP) ([Figure 1D](#fig1){ref-type="fig"}), and transduced this vector into the cells (MDA231-CD/UPRT cells). Second, since thymine can competitively inhibit cellular uptake of 5-FU ([@bib82]), we included thymine in the medium as a competitive inhibitor of 5-FU transport. This dual strategy restricted the anti-BrdU immunostaining to cells expressing CD ([Figure 1E](#fig1){ref-type="fig"}). Thymine was used in all subsequent in vitro and in vivo experiments.

Next, we determined whether this 5-FU-tagging method, 'Flura-tagging', could be used to isolate RNA specifically from cells of interest that were admixed with a large proportion of unlabeled cells. MDA231-CD/UPRT cells were co-cultured with 4T1 mouse breast cancer cells at ratios of 10^−3^ to 10^−4 ^(100 to 1000 MDA231-CD/UPRT cells to 10^6^ 4T1 cells). After 12 hr of incubation with 5-FC, 5-FU-labeled mRNAs were immunoprecipitated with anti-BrdU antibody, and the proportion of human and mouse mRNA for representative housekeeping genes was determined by qRT-PCR. Notably, human mRNAs were enriched by more than 10-fold relative to mouse mRNAs, despite human cells comprising 0.01--0.1% of the total cell population ([Figure 1F](#fig1){ref-type="fig"}). These results demonstrated the efficacy and specificity of the technique in measuring newly synthesized RNAs from small cell populations of interest in a heterogeneous mixture of cells.

To identify potential transcriptional alterations caused by Flura-tagging, we compared the transcriptome of MDA231-CD/UPRT cells treated with two different concentrations of 5-FC (50 μM and 250 μM), with that of untreated cells that do not express CD/UPRT, using global RNA sequencing analysis (RNA-seq). Over 99% of \~20,000 analyzed genes showed statistically similar expression with 50 µM or 250 µM 5-FC ([Supplementary file 1](#supp1){ref-type="supplementary-material"}) indicating that Flura-tagging introduces minimal alteration in the basal transcriptomes of cells in our experimental conditions.

Flura-tagging system effectively captures signal dependent change in gene expression {#s2-3}
------------------------------------------------------------------------------------

To determine whether Flura-tagging could be used to analyze the transcriptional response to extrinsic regulatory signals, we examined the transcriptional response to TGF-β, a pleiotropic cytokine that regulates the expression of many genes involved in diverse cellular processes ([@bib17]). We used the TGF-β response of MDA231 cells ([@bib64]) as an indicator of the sensitivity and fidelity of our method. MDA231-CD/UPRT cells were treated with 5-FC and either TGF-β or the TGF-β receptor kinase inhibitor SB-505124 (SB). We subjected total RNA from MDA231 cells and immunoprecipitated 5-FU-tagged RNA from MDA231-CD/UPRT cells to RNA-seq analysis. In MDA231 cells, 176 genes showed either an increase or decrease of more than two-fold in transcript levels upon TGF-β treatment ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). RNA-Seq analysis of Flura-tagged RNA samples ('Flura-seq') captured the TGF-β transcriptional response of MDA231 cells with high accuracy and fidelity, compared to the RNA-seq control ([Figure 2A,B](#fig2){ref-type="fig"}; [Supplementary file 2](#supp2){ref-type="supplementary-material"}). It is also noteworthy that Flura-seq showed an enhancement in the fold change of the majority of TGF-β induced genes compared to the control ([Figure 2B--D](#fig2){ref-type="fig"}). This is possibly because Flura-seq only detects newly synthesized transcripts, whereas RNA-seq accounts for the total transcripts and thus dilutes the transcriptional response to an acute TGF-β stimulus. On the other hand, Flura-seq identified 575 genes differentially expressed upon TGF-β treatment ([Supplementary file 2](#supp2){ref-type="supplementary-material"}). Comparison of the genes uniquely identified by Flura-seq (2.5 hr post TGF-β treatment) to the differential gene expression data sets in MDA231 cells 6 hr post TGF-β treatment ([@bib78]) showed that 83 of the genes identified only by Flura-seq were induced by TGF-β as detected by RNA-seq at later time points, suggesting that Flura-seq captures early signal-induced gene expression that is missed by RNA-seq due to dilution by the preexisting basal mRNA pool. Collectively, these results show that Flura-seq can accurately capture global changes in gene expression in response to stimuli.

![Flura-tagging system effectively captures signal dependent change in gene expression.\
(**A--D**) MDA231 cells expressing CD/UPRT were treated with 5-FC for 30 min prior to TGF-β or SB-505124 (SB, a TGF-β receptor inhibitor) treatment for 150 min. (**A**) Change in gene expression in TGF-β-treated cells relative to SB-treated cells as determined by RNA-seq of total RNA from control cells or 5-FU-tagged RNA from Flura-tagged cells. The heat map includes all the genes whose expression changed by more than 2-fold (p\<0.01) in response to TGF-β in control cells; (**B**) Cartesian plot of the data in [Figure 2B](#fig2){ref-type="fig"}. Each dot represents a gene; typical TGF-β-responsive genes are highlighted (*n* = 3); (**C**) Violin plot of the genes induced by TGF-β as identified by RNA-seq and Flura-seq, and Flura-seq only; (**D**) Expression of the indicated representative TGF-β-induced genes was determined by qRT-PCR in total RNA and in anti-BrdU immunoprecipitate (*n* = 3,±S.E.). p-Values were calculated by unpaired two-tailed student's t test.](elife-43627-fig2){#fig2}

Flura-seq analysis of rare metastatic cells in situ {#s2-4}
---------------------------------------------------

Next, we determined whether Flura-seq could be used to characterize transcriptomics in situ from a small number of cancer cells disseminated in an intact organ that would be challenging to achieve using existing technologies. MDA231 cells expressing a GFP-luciferase fusion protein for imaging and bioluminescence analysis and Dox-inducible CD/UPRT for Flura-seq analysis, were inoculated into the tail vein of *Foxn1^nu^* immunodeficient mice to allow colonization of the pulmonary parenchyma ([Figure 3A](#fig3){ref-type="fig"}). A small proportion of the injected cells survive in the lungs and initiate metastatic outgrowth ([@bib57]). At day 31 after inoculation, the cancer cell population was present as micrometastatic colonies throughout the pulmonary parenchyma ([Figure 3---figure supplement 1A,B](#fig3s1){ref-type="fig"}). In tissue sections, the size distribution of these colonies ranged from 112 to 877 cells per cluster, with a mean value of 333 cells ([Figure 3---figure supplement 1C](#fig3s1){ref-type="fig"}). CD/UPRT expression was induced by doxycycline treatment on day 28, and mice were administered 5-FC (250 mg/kg) and thymine (125 mg/kg) on day 31 for 4 hr to 12 hr before harvesting the lungs for immunoprecipitation of 5-FU-tagged RNAs ([Figure 3A](#fig3){ref-type="fig"}). The 5-FC dose was selected based on the non-toxic dose of the structurally related thiouracil in mice (250 mg/kg) that has been used for RNA tagging with thiouracil ([@bib28]).

![Flura-tagging of rare metastatic cells in situ.\
(**A**) Schematic diagram of lung colonization xenograft assay used for evaluation of Flura-tagging in vivo. Athymic mice were injected through the tail vein with 50,000 MDA231 cells expressing CD/UPRT and GFP-luciferase. After 4 weeks, mice were treated with doxycycline (3 days) to induce CD/UPRT expression in the disseminated cancer cells, and injected with 5-FC. Lungs were harvested 4 hr to 12 hr later, and subjected to immunopurification of 5-FU-tagged RNA for RNA-seq analysis (Flura-seq); (**B**) Comparison of relative fold enrichment of Flura-tagging and TU-tagging in vivo after immunoprecipitation. Mice with CD/UPRT expressing MDA231 lung metastases were injected with either 5-FC or TU for 12 hr, lungs were harvested. Flura-tagged RNA was purified by immunoprecipitation, and TU-tagged RNA was biotinylated and purified by streptavidin beads. The relative fold enrichment of representative human housekeeping genes relative to representative murine housekeeping genes (*mHPRT1*, *mLDH1*, *mPGK1* and *mGAPDH*), normalized to their corresponding inputs, were determined by qRT-PCR (*n* = 5,±S.E.); (**C**) Flura-seq specifically enriches for 5-FU-tagged human transcripts from lung micrometastases. 5-FU-tagged RNA from mouse lungs bearing CD/UPRT-expressing MDA231 cells and treated with 5-FC for 4 hr or 12 hr were immunopurified and sequenced. RNA reads were aligned to a hybrid genome containing the human and mouse genomes. The percentage of aligned reads mapped to human genome for the Flura-seq samples and the corresponding unprecipitated input is shown (*n* = 2,±S.E.); (**D**) Number of human and mouse genes identified by Flura-seq (samples with 4 hr of 5-FC treatment) at different fold enrichment cutoffs relative to the corresponding unprecipitated inputs (*n* = 2); (**E**) Comparison of the workflow, limitations and sensitivity of Flura-seq versus other methods for transcriptomic analysis of rare cell populations in tissues. p-Values were calculated by unpaired two-tailed student's t test.](elife-43627-fig3){#fig3}

We determined the relative fold enrichment of 5-FU tagging in vivo by measuring the relative capture of representative housekeeping human and mouse transcripts. The human mRNAs were enriched more than a 10,000-fold compared to the corresponding mouse mRNAs ([Figure 3B](#fig3){ref-type="fig"}), indicating that 5-FU tagging occurs primarily in the human cells of interest and that tagged RNAs can be purified efficiently from intact mouse lung tissue. We also compared the relative fold enrichment of 5-FU tagging with TU tagging, an analogous covalent RNA labeling technique ([@bib27]; [@bib56]). To this end, mice harboring lung micrometastases were treated in parallel with TU for 12 hr according to previous studies ([@bib56]). Analysis of tested human mRNAs relative to the mouse mRNAs showed approximately 10-fold enrichment with TU tagging compared to over 10,000-fold enrichment with 5-FU tagging ([Figure 3B](#fig3){ref-type="fig"}). In parallel, we determined the percentage of human cells present in the mouse lungs in these experiments. Approximately 0.003% to 0.08% of the total cell population comprised of human cells, as determined by RFP expression from the polycistronic UPRT/CD/RFP vector ([Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). Since one mouse lung contains approximately 150 million cells ([@bib65]), we estimate that RNA from as few as approximately 5000 human cancer cells per mouse lung could be analyzed by 5-FU tagging ([Figure 3---figure supplement 1E](#fig3s1){ref-type="fig"}).

To determine whether 5-FU tagged mRNA from micrometastatic lesions could be used to characterize the in situ transcriptome of cancer cells, mice were treated with 5-FC for 4 hr or 12 hr, and tagged RNAs were immunopurified and sequenced. The sequenced reads were aligned to a hybrid genome containing both human and mouse genomes, so that reads coming from human or mouse cells could be distinctly identified. In mice treated with 5-FC for 4 hr, approximately 53% of the aligned reads were mapped to human genome, whereas 74% of the aligned reads were mapped to human genome when the mice were treated with 5-FC for 12 hr ([Figure 3C](#fig3){ref-type="fig"}). Fewer than 1% of the mapped reads in the non-immunopurified input samples were aligned to the human genome while 99% of the reads aligned to the mouse genome ([Figure 3C](#fig3){ref-type="fig"}).

To further distinguish transcripts derived from the cells of interest (human cells) versus other cells (mouse cells), we focused on transcripts that were enriched more than 2-fold relative to input. After applying this enrichment cut-off, the reads were aligned to 7487 human genes and 231 mouse genes ([Figure 3D](#fig3){ref-type="fig"}). When the cutoffs were increased to 4, 8 and 16-fold, the number of human genes identified remained the same, whereas the mouse genes were completely eliminated ([Figure 3D](#fig3){ref-type="fig"}). These results demonstrate the sensitivity and specificity of Flura-seq in identifying in situ transcriptomes of cells of interest in vivo ([Figure 3E](#fig3){ref-type="fig"}).

Flura-seq identifies organ-specific in situ transcriptomes in micrometastases {#s2-5}
-----------------------------------------------------------------------------

Next, we applied Flura-seq to define the in situ transcriptomes of breast cancer cells during early stages of metastatic colonization in distinct microenvironments of the brain and lungs. MDA231-CD/UPRT cells were injected intracardially into the arterial circulation of female mice to allow infiltration of multiple organs ([Figure 4A](#fig4){ref-type="fig"}). In the lungs and brain, the cells developed micrometastases within 31 days of injection ([Figure 4---figure supplement 1A](#fig4s1){ref-type="fig"}). The cancer cells were also injected into the mammary fat pad (MFP) to generate orthotopic mammary tumors ([Figure 4A](#fig4){ref-type="fig"}). To identify the genes that are expressed in response to the organ-specific microenvironment, we harvested the brain, lungs, and mammary tumors, and subjected samples to Flura-seq analysis. In parallel, an aliquot of these tissue samples was dissociated into single cells and cultured in selective media to isolate the labeled MDA231 cells as previously described ([@bib57]). Following selection and in vitro expansion for 1--2 weeks (passage 2), these cultures were subjected to RNA-seq analysis ([Figure 4A](#fig4){ref-type="fig"}). Principal component analysis (PCA) revealed that the in situ transcriptomes of MDA231 cells in different tissues were highly divergent from one other ([Figure 4B](#fig4){ref-type="fig"}). In contrast, in vitro culture of the mammary tumor and metastasis-derived cells diminished their transcriptomic differences ([Figure 4B](#fig4){ref-type="fig"}).

![Flura-seq identifies organ specific in situ transcriptomes in micrometastases.\
(**A**) Schematic diagram of experimental design used to obtain tissue specific transcriptomes of MDA231 cells in mice; (**B**) Principal component analysis of genes expressed by MDA231 cells in the indicated organs, as determined by Flura-seq of fresh tissue, or by RNA-seq of in vitro cultured cells derived from these tissues; (**C**) Comparison of differentially expressed genes in metastatic MDA231 cells in different organs as determined by Flura-seq of fresh tissue versus RNA-seq of tissue-derived MDA231 cell cultures. The number of differentially expressed genes and their corresponding fold-change in the indicated organ pairs were plotted for both methods; (**D**) Heatmap representation of differentially expressed genes identified by Flura-seq in MDA231 cells residing in the indicated pairs of organs, compared to the expression of these genes in the third organ.](elife-43627-fig4){#fig4}

Flura-seq identified several thousand genes that were differentially expressed in different tissues whereas the same cells showed differential expression of only a few hundred genes when cultured in vitro ([Figure 4C](#fig4){ref-type="fig"}, [Supplementary file 3](#supp3){ref-type="supplementary-material"}). The majority of organ-specific gene expression changes were not preserved when the cells were isolated from the host tissues and expanded in culture. These results suggested that micrometastases have considerable transcriptional plasticity and dynamically regulate gene expression in response to microenvironmental cues. In situ transcriptomic analysis is therefore critical to capture the phenotypic state of micrometastatic cells in the biologically relevant intact tissue context.

Mitochondrial complex I expression and oxidative stress in lung micrometastatic cells {#s2-6}
-------------------------------------------------------------------------------------

Analysis of in situ organ-specific transcriptomes unexpectedly revealed that lung micrometastases had the highest content of unique transcriptional activity relative to brain micrometastases and mammary tumors, suggesting that distinct requirements exist for successful metastasis initiation in the lung microenvironment ([Figure 4D](#fig4){ref-type="fig"}, [Figure 5---figure supplement 1A](#fig5s1){ref-type="fig"}). Gene Ontology (GO) analysis of the differentially expressed cancer cell genes in the different tissues revealed that genes encoding components of the mitochondrial electron transport chain, particularly genes encoding Complex I subunits, were significantly upregulated in lung metastases relative to both brain metastases and orthotopic mammary tumors ([Figure 5A](#fig5){ref-type="fig"}). Gene set enrichment analysis (GSEA) further confirmed the upregulation of Complex I-encoding genes in lung micrometastases ([Figure 5B](#fig5){ref-type="fig"}). The enrichment of these genes was not observed when the cancer cells were isolated from each organ and cultured in vitro under similar conditions ([Figure 5---figure supplement 1B](#fig5s1){ref-type="fig"}), suggesting that the lung microenvironment drives Complex I expression in metastatic cells. In fact, Complex I genes were underexpressed in lung metastasis-derived cells in culture relative to cells derived from brain metastases or mammary tumors, possibly due to re-adaptation of the cells when removed from the lung microenvironment.

![Mitochondrial Complex I expression and oxidative stress in lung micrometastases.\
(**A**) Gene Ontology (GO) analysis of biological processes (BP) of genes that were upregulated in MDA231 lung micrometastases compared to brain micrometastases or mammary tumors. The top functional groups and their corresponding pvalues are shown (*n* = 3); (**B**) Gene Set Enrichment Analysis (GSEA) analysis of nuclear Complex I genes was performed for the genes identified by Flura-seq in the indicated pairs of MDA231 lung and brain micrometastases and mammary tumors. p-Values were calculated by random permutations; (**C**) Oxidative stress in lung and brain tissue sections containing micrometastases were examined by IHC using anti-4-HNE antibody. Scale bars, 100 μm (top) and 20 μm (bottom); (**D**) Heatmap representation of the expression of genes encoding known antioxidant factors in MDA231 tumors from the indicated organs. The highlighted genes were also upregulated in clinical samples of lung metastasis from breast cancer patients ([Figure 6D](#fig6){ref-type="fig"}); (**E**) IHC analysis of GPX1, an antioxidant gene product identified by Flura-seq to be selectively upregulated in lung micrometastases. Scale bars, 100 μm (top) and 20 μm (bottom); (**F**) IHC analysis of NRF2 in lung and brain micrometastases. Scale bars, 100 μm (top) and 20 μm (bottom); (**G**) GSEA analysis of the NRF2 response gene signature applied to Flura-seq data from the indicated pairs of MDA231 lung and brain micrometastases and mammary tumors (*n* = 3). p-Values were calculated by random permutations.](elife-43627-fig5){#fig5}

Complex I activity is a source of reactive oxygen species (ROS) ([@bib5]; [@bib59]), which at high concentrations cause oxidative stress owing to chemical alteration of proteins and nucleic acids in the cell ([@bib45]; [@bib46]). 4-Hydroxynonenal (4-HNE), a product derived from lipid peroxidation in cells, is a marker of oxidative stress ([@bib46]). A higher level of 4-HNE was present in lung micrometastases compared to the brain micrometastases, as determined by anti-4-HNE immunohistochemistry ([Figure 5C](#fig5){ref-type="fig"}), indicating higher oxidative stress in the lung micrometastases. Cells counteract the cytotoxic effect of oxidative stress by upregulating genes that have antioxidant activity ([@bib24]). Indeed, analysis of the expression of 63 genes that include all the antioxidant enzymes and the proteins that directly detoxify ROS ([@bib29]) revealed that a set of antioxidant genes were specifically upregulated in the lung micrometastases ([Figure 5D](#fig5){ref-type="fig"}). To confirm that the transcriptional changes identified reflect changes in protein levels, we performed immunohistochemistry for one of these gene products, glutathione peroxidase 1 (GPX1), which functions in the detoxification of hydrogen peroxide. Anti-GPX1 immunohistochemistry analysis confirmed high expression GXP1 in lung micrometastases compared to brain micrometastases ([Figure 5E](#fig5){ref-type="fig"}). We also tested whether the organ-specific oxidative stress and antioxidant programs are specific to triple negative breast cancer by analyzing lung and brain micrometastases formed by HCC1954 cell line, a HER2^+^ human breast cancer cell line. The higher oxidative stress and increased expression of antioxidants were also detected in lung micrometastases relative to brain micrometastases in HCC1954 xenograft model ([Figure 5---figure supplement 2A--C](#fig5s2){ref-type="fig"}), indicating that higher oxidative stress and elevated antioxidant program are more general phenomena of early stage lung metastasis in breast cancer.

During oxidative stress, the transcription factor nuclear factor erythroid 2-related factor 2 (NRF2) is stabilized, enabling transcription of an antioxidant transcriptional program ([@bib49]). Lung micrometastases contained high levels of NRF2 compared to brain micrometastases, based on anti-NRF2 immunohistochemistry ([Figure 5F](#fig5){ref-type="fig"}). To determine whether NRF2 transcriptional activity is increased in lung micrometastases, we created a list of 24 NRF2 target genes based on NRF2 chromatin immunoprecipitation-sequencing data curated by Cistrome database ([@bib23]) ([Supplementary File 4](#supp4){ref-type="supplementary-material"}), and performed GSEA analysis on our cancer cell transcriptomes. Indeed, the NRF2 signature was enriched in lung micrometastases compared to brain micrometastases and mammary tumors ([Figure 5G](#fig5){ref-type="fig"}). Like the Complex I genes, the NRF2 responsive genes were underexpressed in lung metastasis-derived cells placed in culture ([Figure 5---figure supplement 1C](#fig5s1){ref-type="fig"}). Collectively, these results show a specific upregulation of Complex I associated with oxidative stress and a strong NRF2 response in breast cancer cells that survive as lung micrometastases.

Organ-specific oxidative stress in human breast cancer lung metastases {#s2-7}
----------------------------------------------------------------------

We investigated Complex I gene expression, and the associated oxidative stress and antioxidant responses in breast cancer patients with metastasis. We analyzed RNA-seq data from breast primary tumors and matched lung metastases from 11 patients ([@bib73]). The lung metastases showed significantly higher expression of Complex I genes compared to mammary tumors ([Figure 6A](#fig6){ref-type="fig"}). Matched pair comparison showed that 73% (8/11) patients had higher expression of Complex I genes in lung metastases than in their matched primary tumors ([Figure 6B](#fig6){ref-type="fig"}). 100% (8/8) of the patients with higher Complex I genes had higher expression of lung-specific antioxidant genes identified by Flura-seq ([Figure 6B](#fig6){ref-type="fig"}), and 88% (7/8) of the patients had higher NRF2 gene signature expression ([Figure 6B](#fig6){ref-type="fig"}).

![Specific oxidative stress in patient-derived lung metastasis tissues.\
(**A--D**) Expression of nuclear Complex I and antioxidant genes in a gene expression data set of matched primary tumors and lung metastases from patients with breast cancer ([@bib73]). (**A**) GSEA analysis of the expression of Complex I genes shows higher expression of these genes in lung metastases (*LM*) compared to primary tumors (*Primary*); (**B**) Complex I genes, lung antioxidant genes (from [Figure 5D](#fig5){ref-type="fig"}), and NRF2 response signature genes are upregulated in lung metastases (*LM*) compared to matched primary tumor (*Pr*). Gene set variation analysis (GSVA) analysis for transcriptomic data from primary tumors and matched lung metastases of individual patients (letter and color coded); (**C**) Association of anti-antioxidant gene expression with mitochondrial Complex I expression in lung metastasis. Patients were divided into two groups based on the upregulation of Complex I genes in the lung metastases relative to their corresponding primary tumor. The Complex I-High group consisted of five patients with more than 25 out of 43 Complex I genes upregulated by more than twofold in lung metastases relative to the corresponding primary tumor. The Complex I-Low group consisted of six patients with less than 25 Complex I genes upregulated by twofold in the lung metastases compared to the corresponding primary tumor. GSVA signature analysis of Complex I genes, lung antioxidant genes, and NRF2 signature genes was performed in the Complex I-High and -Low groups. p-Values were calculated by unpaired two-tailed student's t test; (**D**) Heatmap of the relative expression of individual mitochondrial Complex I genes and antioxidant genes in lung metastases relative to the corresponding primary tumor. Complex I-High and --Low patient samples are shown as separate groups, in order to highlight the association of antioxidant gene expression with Complex I gene expression. *Red dots*, antioxidant genes that were also identified to be upregulated in mouse lung micrometastases by Flura-seq (shown in [Figure 5D](#fig5){ref-type="fig"}); (**E, F**) IHC analysis of oxidative stress marker 4-HNE (**E**) and NRF2 (**F**) in tissue microarrays of brain metastases (*BrM*) and lung metastases (*LM*) from breast cancer patients. Shown are representative images and the quantifications based on the degree of staining (0, no signal: 3, highest signal). (*n* = 55 samples for BrM and *n* = 45 for LM for 4-HNE; *n* = 48 for BrM and *n* = 41 for LM for NRF2). Scale bar, 20 μm; (**G**) Association between oxidative stress (4-HNE) and NRF2 scores in lung metastases and brain metastases of breast cancer patients. Heatmap of the IHC staining of 4-HNE (**E**) and NRF2 (**F**) was plotted for each patient sample in the TMAs; (**H**) Hazard Ratio plots of the predictive ability of NRF2 signatures in brain (BrM), lung (LM) and bone (BM) metastasis-free survival outcomes in EMC-MSK dataset (GSE2603, GSE5327, GSE2034 and GSE12276). p-Values were calculated using Log-rank test.](elife-43627-fig6){#fig6}

A closer examination of differentially expressed genes (\>2 fold) in lung metastases compared to their corresponding primary tumors revealed that 45% (5/11) patients overexpressed 26--39 out of 43 nuclear encoded Complex I genes ([Supplementary File 5](#supp5){ref-type="supplementary-material"}). We divided these patients into two groups: a high Complex I group of five patients with upregulation of more than 25 Complex I genes, and a low Complex I group of remaining six patients. Complex I high patients were specifically associated with higher expression of lung antioxidant genes and NRF2 signature genes ([Figure 6C,D](#fig6){ref-type="fig"}), supporting the conclusion that the high expression of Complex I in lung metastasis is associated with the expression of compensatory antioxidant programs. Moreover, eight antioxidant genes that were upregulated together with Complex I genes in patients' lung metastases ([Figure 6D](#fig6){ref-type="fig"}) were also upregulated in Flura-seq transcriptomes from experimental lung micrometastases (refer to [Figure 5D](#fig5){ref-type="fig"}).

Finally, we sought to determine whether the differences in oxidative stress and antioxidant responses in lung vs. brain metastases were conserved in clinical samples from breast cancer patients. We performed immunohistochemistry for 4-HNE and NRF2 on a tissue microarray (TMA) containing lung metastases and brain metastases from more than 40 breast cancer patients. Consistent with the Flura-seq findings, 93% (42/45) of the lung metastases scored high for 4-HNE immunostaining, whereas only 16% (9/55) of brain metastases did ([Figure 6E](#fig6){ref-type="fig"}). Likewise, 78% (32/41) of the lung metastases scored high for NRF2 immunostaining versus only 30% (14/48) in the brain metastases ([Figure 6F](#fig6){ref-type="fig"}). There was a strong association between oxidative stress (4-HNE) and NRF2 protein level in majority of the patients ([Figure 6G](#fig6){ref-type="fig"}). Collectively, these results demonstrate higher oxidative stress and elevated protective antioxidant program in lung metastases compared to brain metastases in breast cancer patients.

To test if the NRF2 signature genes overexpression in breast cancer tumors correlate with organ-specific metastasis prognosis outcomes, we calculated the Hazard ratio for NRF2 signature genes for lung, brain and bone metastasis in breast cancer patients. We found that the Hazard ratio was significantly different for lung metastasis but not for brain and bone metastasis ([Figure 6H](#fig6){ref-type="fig"}), indicating that NRF2 overexpression is advantageous for the survival of breast cancer cells in the lungs compared to brain or bone.

Discussion {#s3}
==========

Organ-specific metabolic adaptation of metastasis-initiating cells {#s3-1}
------------------------------------------------------------------

Previous studies have identified stable, organ-specific transcriptomic programs in cancer cells that were selected on the basis of their ability to form macrometastases and then isolated from these lesions by FACS or in vitro culture prior to transcriptomic analysis ([@bib69]; [@bib41]; [@bib57]; [@bib8]; [@bib7]; [@bib15]; [@bib50]; [@bib10]; [@bib37]; [@bib1]). Although these methods successfully identify heritable transcriptional alterations of clinical relevance, these approaches overlook the dynamic transcriptional states that are dependent on tissue-specific microenvironmental cues. Flura-seq now enables the highly sensitive capture of these dynamic transcriptional states, thus shedding light on crucial adaptive processes underway in micrometastases that could not previously be identified.

In this study, we applied Flura-seq to identify the in situ transcriptomic programs that are differentially active in cancer cells at early stages of metastatic colonization in the lungs and brain. We identified metabolic gene signatures that were specific to the colonized organ and lost upon removing cancer cells from the tissue microenvironment and placing them in culture. Specifically, we identified mitochondrial Complex I as the top upregulated transcriptional alteration in lung metastases that was dynamic and dependent on an intact tissue microenvironment. Elevated expression of Complex I genes correlated with increased oxidative stress and activation of counteracting antioxidant programs including the upregulation of a distinct set of NRF2-driven antioxidant genes in metastatic cells that seed the lungs. Antioxidant and NRF2 activity were also increased in association with high Complex I expression in lung metastases from breast cancer patients, suggesting a role of these pathways in mitigating the cytotoxic effects of oxidative stress on lung metastatic cells. Lung tissue is exposed to higher concentration of oxygen compared to other organs ([@bib39]), and high oxygen concentration can cause oxidative stress ([@bib31]). It is therefore possible that higher oxygen concentration in the lung micrometastases drives the observed changes. However, we cannot rule out other lung specific microenvironmental cues such as metabolites, cytokines, physical stress, or immune surveillance as sources of the observed changes.

These results demonstrate that metastatic tumor cells arising from a single source adopt unique transcriptional profiles depending on their site of colonization. Despite increasing appreciation that metastatic outgrowths frequently exhibit altered metabolic gene expression compared to their primary tumor counterparts ([@bib44]; [@bib20]; [@bib13]), whether these metabolic transitions result from the outgrowth of a selected subpopulation predisposed to thrive in a particular location or from the dynamic adaptation of cancer cells to a changing microenvironment remains an open question. Our results support a model wherein tumor cells dynamically adapt to local conditions and suggest that a major determinant of the metabolism of metastatic cells is the site of colonization. These metabolic rearrangements are likely an early event in the establishment of metastatic seeding and may represent a targetable bottleneck against the growth of metastatic lesions.

Oxidative stress with clinical implications in metastasis {#s3-2}
---------------------------------------------------------

Oxidative stress has been implicated in metastasis, however, the precise role of the stress in metastasis has remained controversial. On one hand, oxidative stress has been observed in cancer cells soon after detachment from epithelia ([@bib70]), and it persists during circulation ([@bib44]) and upon colonization of metastatic sites in model systems ([@bib66]; [@bib30]). The lung has been proposed to have pro-oxidant environment due to high oxygen and toxins exposure ([@bib71]), and anti-oxidative mediators such as NRF2 ([@bib80]; [@bib18]; [@bib55]), peroxiredoxin 2 ([@bib75]) and thioredoxin-like 2 ([@bib68]) stimulate the progression of lung cancer and lung metastasis. On the other hand, ROS has also been reported to promote metastasis, and antioxidants have been shown to inhibit metastasis ([@bib25]; [@bib38]; [@bib67]). The oxidative state and the role of oxidative stress soon after the metastatic cancer cells seed the distant organs before they form macrometastases remain unknown. Our findings demonstrate high oxidative stress in the lung micrometastases of breast cancer, supporting the idea that antioxidant programs promote the progression of lung metastasis and highlighting a critical role for antioxidant mediators in the transition of micrometastases to overt metastases.

Surprisingly, however, our data suggest that elevated antioxidant defenses are not a universal hallmark of metastatic lesions. We found that breast cancer brain metastases experience a low level of oxidative stress and antioxidative response. Given that metastatic cells can exhibit reversible metabolic alterations ([@bib66]), these results raise the possibility that tumor cells undergo multiple metabolic transitions in order to adapt to the changing microenvironments encountered during the metastatic cascade. Indeed, recent evidence suggests that cancer cells from disparate origins may converge to adopt metabolic phenotypes in a given organ ([@bib71]; [@bib51]). Techniques such as Flura-seq that enable in situ interrogation of tumor cell phenotypes can reveal to what extent these various metabolic transitions are driven by adaptation to the specific microenvironment versus selection of cancer cells with preexisting traits. Given increasing evidence that cell lineage is a critical determinant of cancer cell metabolism ([@bib54]; [@bib83]) it will be interesting for future studies to determine whether lineage-specific metabolic predispositions contribute to the metastatic organ tropisms of different tumor types. More broadly, these studies will help to shed light on the precise factors in the tissue microenvironment that contribute to organ-specific metabolic profiles.

Flura-seq as an in situ transcriptomic technique with broad biological applications {#s3-3}
-----------------------------------------------------------------------------------

Preservation of the intact tissue microenvironment is critical to accurately elucidate the transcriptional state of a cell in vivo. Flura-seq can define in situ transcriptomes from a very rare cell population representing a small fraction (\>0.003%) of an organ. The superior sensitivity of Flura-seq compared to related TU-tagging and EC-tagging may be due to the elimination of a biotinylation step and RNA purification system that distinguishes between cytosine derivatives and uracil derivatives. Flura-seq can be easily applied to any cell type that constitutes a rare subpopulation within the host tissue, such as stem cells and specific subtypes of immune and neuronal cells, in addition to residual cancer cells populations during early stages of metastasis or following the shrinking of a tumor with current therapies.

Another feature of Flura-seq is that it only identifies newly synthesized transcripts, which is an advantage in the study of transcriptional responses to cytokines, metabolites, pharmacologic agents, stress signals, and other factors that act by rapidly changing the transcriptomic state of target cells. Further, since Flura-seq involves covalently labeling RNA, it can complement other techniques such as scRNA-seq to combine in situ transcriptomic analysis with profiling of the dissociated cell population with single-cell resolution. Recent advances in scRNA-seq have significantly expanded the application of this technology to the analysis of underrepresented cell types in tissues; however, the method requires extensive physical and enzymatic processing that destroys the tissue microenvironment, and thus microenvironment-dependent gene expression features cannot be accurately captured by scRNA-seq. The higher coverage and applicability of Flura-seq to any tissues and cell types is the principal benefit of Flura-seq over scRNA-seq.

Flura-seq involves the expression of exogenous enzymes, CD and UPRT, and treatment of cells or mice with 5-FC. These treatments may alter the levels of certain transcripts, and is therefore important to validate findings made by Flura-seq with alternative methods such as immunostaining, as shown here. This limitation notwithstanding, Flura-seq provides a sensitive, robust and economical alternative to existing in situ transcriptomics techniques. Thus, the power of Flura-seq in studying rare cell populations can be harnessed to address challenging questions of high biological and clinical significance.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\        Designation                  Source or reference                         Identifiers                                                         Additional\
  (species) or\                                                                                                                                                     information
  resource                                                                                                                                                          
  -------------------- ---------------------------- ------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------
  Antibody             anti-BrdU; BrdU\             Abcam                                       Cat\#ab6326                                                         (1:200)
                       antibody\                                                                                                                                    
                       (Rat monoclonal)                                                                                                                             

  Antibody             anti-CD31; CD31\             Dianova                                     Cat\#DIA-310                                                        (1:100)
                       antibody\                                                                                                                                    
                       (Rat monoclonal)\                                                                                                                            

  Antibody             anti-GFP; GFP\               Aves Labs                                   Cat\#GFP-1020                                                       (1:500)
                       antibody (Chicken\                                                                                                                           
                       monoclonal)                                                                                                                                  

  Antibody             anti-4-Hydroxynonenal;\      Abcam                                       Cat\#ab46545                                                        (1:75)
                       4-HNE antibodyl\                                                                                                                             
                       (Rabbit polyclonal)                                                                                                                          

  Antibody             anti-NRF2; NRF2\             Abcam                                       Cat\#ab137550                                                       (1:600)
                       antibody (Rabbit\                                                                                                                            
                       polyclonal)                                                                                                                                  

  Antibody             anti-Glutathione\            Abcam                                       Cat\#ab22604                                                        (1:200)
                       Peroxidase 1;\                                                                                                                               
                       GPX1 antibody\                                                                                                                               
                       (Rabbit polyclonal)                                                                                                                          

  Antibody             Goat polyclonal\             Thermo Fisher                               Cat\#A-11039                                                        (1:1000)
                       anti-chicken                                                                                                                                 

  Antibody             Goat polyclonal\             Thermo Fisher                               Cat\#A-11006                                                        (1:1000)
                       anti-rat                                                                                                                                     

  Antibody             Goat polyclonal anti-mouse   Abcam                                       Cat\#ab150117                                                       (1:1000)

  Biological\          Human breast\                This paper (Section\                        N/A                                                                 Tissue microarray Available from\
  sample (Human)       cancer lung\                 of lung tissue\                                                                                                 Edi Brogi
                       metastases tissue\           containing cancer cells\                                                                                        
                       microarray (TMA)             was surgically removed\                                                                                         
                                                    from breast cancer\                                                                                             
                                                    patients, preserved in\                                                                                         
                                                    paraflim and a small\                                                                                           
                                                    portion of the\                                                                                                 
                                                    preserved tumor was\                                                                                            
                                                    used to make the TMA)                                                                                           

  Chemical\            Doxycycline                  Sigmal-Aldrich                              Cat\#D9891                                                          
  compound, drug                                                                                                                                                    

  Chemical\            5-Fluorocytosine; 5-FC       Sigma-Aldrich                               Cat\#F7129                                                          
  compound, drug                                                                                                                                                    

  Chemical\            5-Fluorouracil; 5-FU         Sigma-Aldrich                               Cat\#F6627                                                          
  compound, drug                                                                                                                                                    

  Chemical\            SB-505124                    Sigma-Aldrich                               Cat\#S4696                                                          
  compound, drug                                                                                                                                                    

  Chemical\            Thymine                      Sigma-Aldrich                               Cat\#T0376                                                          
  compound, drug                                                                                                                                                    

  Chemical\            4-Thiouracil; TU             Sigma-Aldrich                               Cat\#440736                                                         
  compound, drug                                                                                                                                                    

  Other                Oligo (dT)~25~ magnetic\     New England Biolabs                         Cat\#S1419S                                                         
                       beads                                                                                                                                        

  Other                Protein G Dynabeads          Thermo\                                     Cat\#10004D                                                         
                                                    Fisher Scientific                                                                                               

  Commercial\          Tissue digestion\            Miltenyi                                    Cat\#130-096-334                                                    
  assay or kit         C-tube                                                                                                                                       

  Commercial\          Mouse Tumor\                 Miltenyi                                    Cat\#130-096-730                                                    
  assay or kit         Dissociation Kit                                                                                                                             

  Commercial\          TruSeq RNA Library\          Illumina                                    RS-122--2001                                                        
  assay or kit         Prep Kit v2                                                                                                                                  

  Commercial\          SMARTer PCR\                 Clontech                                    Cat\#634926                                                         
  assay or kit         cDNA synthesis kit                                                                                                                           

  Commercial\          Nextera XT DNA\              Illumina                                    FC-131--1024                                                        
  assay or kit         library Preparation Kit                                                                                                                      

  Commercial\          RNeasy MinElute\             Qiagen                                      Cat\#74204                                                          
  assay or kit         Cleanup kit                                                                                                                                  

  Commercial\          cDNA kit-First\              Roche                                       Cat\#043790--12001                                                  
  assay or kit         Strand Transcriptor                                                                                                                          

  Cell line (Human)    MDA231                       Laboratory of\                              PMID: 19421193                                                      Expresses TGL
                                                    Joan Massague                                                                                                   

  Cell line (Human)    MDA231-CD                    This paper (MDA231\                         N/A                                                                 Available from\
                                                    cells were transduced\                                                                                          Massague lab
                                                    with rtTA3 and TRE-CD-IRES-RFP)                                                                                 

  Cell line (Human)    MDA231-CD/UPRT               This paper (MDA231 cells were transduced\   N/A                                                                 Available from\
                                                    with rtTA3 and\                                                                                                 Massague lab
                                                    TRE-UPRT-T2A-RFP-IRES-CD)                                                                                       

  Cell line (Human)    293T                         Laboratory of\                              N/A                                                                 
                                                    Joan Massague                                                                                                   

  Strain, strain\      Hsd:Athymic\                 Envigo                                      Cat\#069                                                            
  background (*Mus*\   Nude- Foxn1^nu^                                                                                                                              
  *musculus)*                                                                                                                                                       

  Sequence-based\      Oligonucleotides             This paper                                  N/A                                                                 Oligonucleotide\
  reagents                                                                                                                                                          sequences are provided\
                                                                                                                                                                    in [Supplementary file 6](#supp6){ref-type="supplementary-material"}

  Recombinant\         CMV Tight RFP-IRES-CD        This paper (RFP-IRES-CD\                    N/A                                                                 Available from\
  DNA reagent                                       was subcloned\                                                                                                  Massague lab
                                                    into CMV Tight EGFP\                                                                                            
                                                    Puro (Addgene:\                                                                                                 
                                                    Plasmid \#26431) vector by\                                                                                     
                                                    removing EGFP).                                                                                                 

  Recombinant\         CMV Tight UPRT-\             This paper\                                 N/A                                                                 Available from\
  DNA reagent          T2A-RFP-IRES-CD              (UPRT-T2A-RFP-IRES-CD\                                                                                          Massague lab
                                                    was subcloned into\                                                                                             
                                                    CMV Tight EGFP\                                                                                                 
                                                    Puro (Addgene: Plasmid\                                                                                         
                                                    \#26431) vector by\                                                                                             
                                                    removing EGFP).                                                                                                 

  Recombinant\         rtTA3                        Addgene                                     Plasmid \#26730                                                     
  DNA reagent                                                                                                                                                       

  Software and\        STAR2.5.2b                   PMID: 23104886                              <https://github.com/alexdobin/STAR>                                 
  Algorithms                                                                                                                                                        

  Software and\        HTSeq v0.6.1p1               PMID: 20979621                              <https://htseq.readthedocs.io/en/release_0.10.0/>                   
  Algorithms                                                                                                                                                        

  Software and\        DESeq2 v3.4                  PMID: 25516281                              <https://bioconductor.org/packages/release/bioc/html/DESeq2.html>   
  Algorithms                                                                                                                                                        

  Software and\        GSVA v3.4                    PMID: 23323831                              <https://bioconductor.org/packages/release/bioc/html/GSVA.html>     
  Algorithms                                                                                                                                                        
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Cell culture {#s4-1}
------------

Human embryonic kidney cells transformed with T-cell antigen (293T) and human breast cancer MDA-MB-231 (MDA231) cells were cultured in DMEM High Glucose medium (Wheaton) supplemented with 10% fetal bovine serum and 2 mM L-glutamine. All cell lines have been regularly tested for mycoplasma contamination, and the identity of the cell lines have been authenticated by STR profiling. For the induction of CD or CD/UPRT, cells were treated with 1 μg/ml doxycycline for 24 hr. For 5-FU tagging, cells were treated with 250 μM 5-FC or 5-FU unless indicated. Where indicated, 125 μM thymine was added together with 5-FC. For the induction of TGF-β target genes, cells were treated with 200 pM TGF-β or 2.5 μM SB-505124 for 150 min. For 5-FU-tagging during TGF-β treatment, cells were treated with 5-FC and thymine for 30 min before adding TGF-β or SB-505124.

Animal experiments {#s4-2}
------------------

Mouse experiments were performed following the protocols approved by the MSKCC Institutional Animal Care and Use Committee (IACUC). Five- to six-week-old female mice (*Mus musculus*) Hsd:Athymic-Foxn1^nu^ were used in all the experiments. For lung colonization experiments, 50,000 MDA231 cells suspended in 100 μl PBS were injected into the tail vein. For organ-specific metastasis experiments, 50,000 MDA231 cells or 100,000 HCC1954 cells suspended in 100 μl PBS were injected intracardially. For mammary fat pad injection, 50,000 MDA231 cells in 50 μl PBS were mixed with 50 μl matrigel and the mixture was injected in the fat pad of mammary gland \#4. Proliferation of injected cancer cells was quantified using bioluminescence imaging following retro-orbital injection of D-luciferin (Gold Biotechnology). CD/UPRT expression was induced by feeding mice doxycycline diet for 2--3 days. For Flura-tagging, mice were injected with 250 mg/kg (500 μl) 5-FC intraperitoneally together with 125 mg/kg (500 μl) thymine subcutaneously. For thiouracil-tagging, mice were injected intraperitoneally with 250 mg/kg (500 μl) of 4-thiouracil. The mice were euthanized 4--12 hr post injection, lungs and brain were harvested and processed for downstream experiments. For RNA analysis, lungs were dissociated using the PRO 200 grinder from PRO Scientific Inc. in RNA extraction lysis buffer. The lung lysates were either used immediately for mRNA extraction or stored at −80°C for later use.

Immunofluorescence (IF) and Immunohistochemistry (IHC) {#s4-3}
------------------------------------------------------

For IF, cells were fixed with 4% paraformaldehyde for 10 min, permeabilized with 0.2% TritonX-100 for 10 min, blocked with 5% BSA for 1 hr at room temperature, prior to incubation with primary antibodies at 4°C overnight, and secondary antibodies incubated for 1 hr at room temperature. Mouse lung and brain were fixed in 4% paraformaldehyde 24--48 hr at 4°C, embedded in paraffin and sectioned at 5 μm. Paraffin-embedded sections or tissue microarrays were rehydrated using Histo-Clear (National Diagnostics) followed by 100-95--70% ethanol and water. Antigen retrieval was performed in a steamer for 30 min in citrate antigen retrieval solution. Tissue sections were blocked with 5% normal goat serum for 1 hr, and incubated with primary antibodies overnight. Secondary antibodies conjugated with fluorophores were used for detection. IHC were performed on BOND RX (Leica Biosystems) using standard Epitope Retrieval Solution 2 (Leica Biosystems) for 30 min followed by primary antibody incubation for 30 min and BOND polymer refine detection kit-DAB. Automated image analysis was performed using the FIJI software package. Human histopathological sections were obtained under a biospecimen protocol approved by the MSK Institutional Review Board. All human pathology analyses were performed under the supervision of an experienced breast pathologist (E.B.).

Flura-tagged and TU-tagged mRNA extraction {#s4-4}
------------------------------------------

Cells or tissues were lysed in lysis buffer (20 mM Tris-HCl pH 7.5, 500 mM LiCl, 1% LiDS, 1 mM EDTA, 5 mM DTT), and mRNAs were extracted using Oligo (dT)~25~ magnetic beads following the manufacturer's protocol. The isolated mRNAs were immunoprecipitated using anti-BrdU antibody (1--5 μg/sample) conjugated with Protein G Dynabeads by overnight incubation at 4°C. The mRNAs were incubated with the antibody bead complex in 0.8X Binding buffer (0.5X Sodium Chloride-Sodium Phosphate-EDTA (SSPE) with 0.025% Tween 20) at room temperature for 1--2 hr in a rotator. Subsequently, beads were washed twice with Binding buffer, twice with Wash buffer B (1X SSPE with 0.05% Tween 20), once with Wash buffer C (TE with 0.05% Tween 20), and once with TE buffer. The bound mRNAs were eluted in 200 μl of 100 μg/mL BrdU for 45 min in a shaker at room temperature. The eluted RNAs were purified using the RNeasy MinElute Cleanup kit following the manufacturer's protocol. The RNA was eluted in 100 μl RNAase free water. The Flura-tagged RNA elute were re-precipitated as described above, and eluted in 12.5 μl final volume. The RNA was either reverse-transcribed using cDNA kit-First Strand Transcriptor following the manufacturer's protocol, or used for Flura-Seq. TU-tagged mRNAs were purified as described in [@bib56].

Isolation of organ-derived cancer cells {#s4-5}
---------------------------------------

Brain, lung or mammary tumors were cut into small fragments (around 1 mm^3^) and transferred to a tissue digestion C-tube. The tumor pieces were incubated with mouse Tumor Dissociation Kit and further dissociated mechanically on a gentleMACS Dissociator as per manufacturer's protocol. The digestion reaction was stopped with albumin-rich buffer (RPMI-1640 medium containing 0.5% bovine serum albumin (BSA)). A single-cell suspension was obtained by filtering through a 70 μm cell strainer. The cells were then cultured in DMEM High Glucose media containing 10% FBS, 2 mM L-Glutamine, 200 μg/mL Hygromycin and 8 μg/mL Blasticidin to select MDA231 cells.

Flow cytometry {#s4-6}
--------------

Harvested lungs were chopped into small pieces (around 1 mm^3^), which were then incubated at 37°C in 30 mL digestion buffer (5% Fetal Bovine Serum (FBS) 1 mM L-glutamine 0.35 mg/mL Worthington Type III collagenase, 6.25 × 10^−3^ U/mL dispase, 100 U/mL penicillin, 100 μg/mL streptomycin, 6.25 ng/mL amphotericin B) containing 10 mL trypsin and 30 μl DNAse for 1 hr. The cells were filtered through a 70 μM filter, and were collected by centrifugation. The cell pellets were then resuspended in PBS containing 0.1% FBS and 100 μg/ml DAPI, and analyzed using a BD FACS Aria IIU Flow cytometer. CD or CD/UPRT expressing stable cell lines were treated with 1 μg/mL doxycycline for 24 hr, trypsinized, filtered and sorted for RFP positive cells using a BD LSRFortessa Flow cytometer.

RNA sequencing {#s4-7}
--------------

RNA-seq library preparation. Total RNA was purified using Qiagen RNeasy Mini Kit. Quality and quantity of the RNA were checked using an Agilent BioAnalyzer 2000. 10 ng of RNA per sample was used for library construction with Sample Prep Kit v2 according to manufacturer's instructions. Libraries were multiplexed on a Hiseq2500 platform, and more than 25 million raw paired-end reads were generated for each sample.

Flura-seq library preparation. RNA was amplified by SMARTer PCR kit with the number of PCR cycles determined empirically based on the amount of purified 5-FU-tagged RNA. The Nextera XT kit was used to prepare sequencing libraries following the manufacturer's protocol. In our in vivo experiments, 20--24 cycles of PCR were used.

Statistics and data analysis {#s4-8}
----------------------------

In all relevant experiments, mice were randomized prior to different treatments. Comparisons between samples were done in the gene expression analysis, and each group had 2--3 biological replicates that are indicated in the figure legends for each experiment. In the in vitro experiments, biological replicates are samples derived from cells that were plated and processed separately. In the in vivo experiments, the biological replicates represent individual mouse. *N* described in the Figure legends represents independent biological replicates. The technical replicates are originated from the same sample but divided into different groups. Sample size for each experiment was determined empirically.

Reads were quality checked using FastQC v0.11.5 and mapped to a human (hg19) or hybrid human-mouse (hg19-mm10) genome with STAR2.5.2b ([@bib19]) using standard settings for paired reads. Uniquely mapped reads were assigned to annotated genes with HTSeq v0.6.1p1 ([@bib2]) with default settings. Read counts were normalized by library size, and differential gene expression analysis based on a negative binomial distribution was performed using DESeq2 v3.4 ([@bib48]). In general, thresholds for differential expression were set as follows: adjusted p value\<0.05, fold change \>2.0 or\<0.5, and average normalized read count \>10. Genes were considered detectable in the immunoprecipitation samples with a normalized read count \>100. Gene set enrichment analysis was performed using GSVA v3.4 ([@bib33]) and previously curated gene sets ([@bib76]). GSEA mountain plots were generated by 'liger' R package (V0.1).

Plasmids generation {#s4-9}
-------------------

Primers used for cloning the constructs described in the manuscript are described in [Supplementary file 6](#supp6){ref-type="supplementary-material"}. CD (Addgene 35102), and UPRT (Addgene 47110) were used as template for PCR for subcloning. RFP and IRES were amplified using pTRIPZ (Dharmacon) as template. The PCR products were either ligated using DNA Ligase after restriction enzyme digestion and/or by Gibson Assembly.
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###### Genes that are differentially expressed in MDA231 cells expressing CD/UPRT and treated with indicated concentration of 5-FC for 4 hr compared to control cells were obtained by DESEQ2 analysis.

10.7554/eLife.43627.015

###### Genes that are differentially expressed in TGF-β treated cells compared to SB-505124 by more than twofold are shown as identified by RNA-seq and Flura-seq.

Genes commonly identified by RNA-seq 6 hr post TGF-β, but not 2.5 hr post treatment, and Flura-seq 2.5 hr post TGF-β treatment are also shown.

10.7554/eLife.43627.016

###### Genes that are differentially expressed in MDA231 cells in different organs in situ as determined by Flura-seq or in vitro after isolation from the organs as determined by RNA-seq are shown.

10.7554/eLife.43627.017

###### Top 100 NRF2 target genes identified by two independent ChIP-seq experiments in Hela cells ([@bib23]), and the genes that were common in both experiments were used as NRF2-responsive signature genes.

10.7554/eLife.43627.018

###### Genes identified to be up-regulated by more than two-fold in lung metastases compared to the corresponding primary tumors in breast cancer patients described in [@bib73] for each patients are shown.

Complex I genes are highlighted in red color and the total number of upregulated Complex I genes in each patient is shown.

10.7554/eLife.43627.019

###### Oligonucleotide sequences used in the experiments described in the manuscript are shown.

10.7554/eLife.43627.020

Data availability {#s7}
=================

Sequencing data have been deposited in GEO under accession codes GSE93605 and GSE118937.

The following datasets were generated:

BasnetHTianLMassagueJ2018Organ-specific in situ transcriptomics of MDA231 cells identified by Flura-seqNCBI Gene Expression OmnibusGSE118937

BasnetHMacalinaoDGMassagueJ2017Flura-seq of TGFB treated MDA231 cellsNCBI Gene Expression OmnibusGSE93605

The following previously published datasets were used:

SiegelMPerouC2018Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancerNCBI Gene Expression OmnibusGSE110590

MinnAJMassagueJ2005ubpopulations of MDA-MB-231 and Primary Breast CancersNCBI Gene Expression OmnibusGSE2603

WangYFoekensJMinnAMassagueJ2007Breast cancer relapse free survival and lung metastasis free survivalNCBI Gene Expression OmnibusGSE5327

WangYKlijnJGZhangYSieuwertsAM2005Breast cancer relapse free survivalNCBI Gene Expression OmnibusGSE2034

BosPDMassagueJ2009Expression data from primary breast tumorsNCBI Gene Expression OmnibusGSE12276

10.7554/eLife.43627.036

Decision letter

Vander Heiden

Matthew G

Reviewing Editor

Massachusetts Institute of Technology

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Flura-seq identifies organ-specific metabolic adaptations during early metastatic colonization\" for consideration by *eLife*. Your article has been reviewed by two peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Sean Morrison as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The paper is interesting, though both reviewers commented that the uniqueness of the technique was overstated and raised technical questions that should be addressed in a revised manuscript. I have summarized the specific points from the reviewers that should be addressed.

Summary:

The study presents a new technique called Flura-seq for transcriptomic analysis of rare cell populations in tissues. This approach is based on 5-FU labeling of nascent RNAs in cytosine deaminase-expressing cells. After validating the approach in cell lines it was used to characterize the transcriptome of rare metastatic cells in vivo. They describe organ specific gene expression signatures and focus on the fact that lung micrometastatic cells have higher expression levels of electron transport chain as well as antioxidant genes, and confirm these findings in human breast cancer metastases.

Essential revisions:

1\) With recent advances in single cell RNA sequencing, please discuss how this technique differs and, if possible, comment on how it performs in comparison to the more widely used single cell RNA sequencing approaches. A discussion of where Flura-Seq should be used instead of scRNA-seq would increase the impact of the paper.

2\) Given that Flura-seq requires the overexpression of cytosine deaminase and uracil phosphoribosyl transferase, the administration of 5FU and thymine and a relatively short-term assay, these limitations should be more fully discussed. Also, the authors should not completely discount existing approaches that are relevant to these questions including laser capture microdissection/RNA-seq and SLAM-ITseq.

3\) In Figure 3C, it was noted that only 53 to 74% of the aligned reads were mapped to the human genome after IP in 5-FC treated mice. Does it mean that 26 to 47% of the reads are derived from contaminating mouse reads? What does this mean for the efficacy of the staining and IP purification? Can one then trust that all the human reads correspond to stained RNA of actively transcribed genes with such a noisy technique? How good is the qPCR to assess the signal-to-noise ratio of the technique (for example Figure 3B) and why is there such a discrepancy between Figure 3B and 3C results?

4\) In Figure 4D, it was claimed that lung micrometastases have the highest content of unique transcriptional activity. However, what is lacking is an objective quantification of this uniqueness. This result is the reason why the remainder of the paper focuses on the specificity of the lung versus brain metastases and electron transport chain (ETC)/antioxidant gene expression levels, so this should be more convincing.

5\) Please comment on whether the main findings could be explained by the higher oxygen levels in the lung tissue compared to the brain and mammary fat pad. It is well known that high oxygen can lead to high levels of oxidative stress. This seems to be confirmed by the basal 4-HNE, GPX1 and NRF2 stainings in normal lung tissue, which are equally high as in the lung metastases and higher than in normal brain tissue (Figure 5C, E, F). Finally, in the comparison of in vitro cultures for example, the high oxygen levels could also be responsible for the loss of differences in the transcriptional profiles of ex vivo cultures from different organs (Figure 4B).

6\) In co-culture experiments to assess the sensitivity of Flura-seq (Figure 1F), could the authors comment on why there isn\'t higher signal of human housekeeping genes in the samples when there are 10-fold more human cells?

7\) Many of the RNAs downregulated in TGFb control samples are also reduced in the Flura-seq samples, which seems surprising given the short 30 minute 5-FC labeling period. Was the signal for these genes low relative to the control samples, as expected? To assess this, it would be helpful to see the normalized count values for each condition in the supplemental tables (not just fold-change). Also, are there differentially expressed transcripts identified by Flura-seq that are not found in the control samples? Are they known TGF-b targets? Potential false-positives?

8\) Please clarify or reference how the 24 genes for the NRF2 signature were selected.

9\) Please ensure that statistical significance of the results is addressed throughout, including in Figure 1F (where the SD is large), 2C, and 3B-C.

10.7554/eLife.43627.037

Author response

> Essential revisions:
>
> 1\) With recent advances in single cell RNA sequencing, please discuss how this technique differs and, if possible, comment on how it performs in comparison to the more widely used single cell RNA sequencing approaches. A discussion of where Flura-Seq should be used instead of scRNA-seq would increase the impact of the paper.

We appreciate the reviewers' suggestion. In the revised manuscript, we have added more details on the application of scRNA-seq in studying rare cells and highlighted its limitations that can be addressed by Flura-seq. Comments to this effect are included in the Introduction (third paragraph) and Discussion sections (subsection "Flura-seq as an in situ transcriptomic technique with broad biological applications"). Briefly, scRNA-seq requires disruption of tissue microenvironment to obtain single cells, and thus altering in situ transcriptiomic information. Furthermore, the low transcript coverage and the inapplicability to tissue and cell types that cannot be isolated into single cells remains a limitation of scRNA-seq.

> 2\) Given that Flura-seq requires the overexpression of cytosine deaminase and uracil phosphoribosyl transferase, the administration of 5FU and thymine and a relatively short-term assay, these limitations should be more fully discussed. Also, the authors should not completely discount existing approaches that are relevant to these questions including laser capture microdissection/RNA-seq and SLAM-ITseq.

We agree that Flura-seq may alter certain transcripts because of CD and UPRT expression and 5-FC treatment. Therefore, it is critical to validate the discovery made by Flura-seq by alternative methods such as immunostaining, as shown in the present work. We acknowledge this caveat in the Discussion (subsection "Flura-seq as an in situ transcriptomic technique with broad biological applications"). We have discussed the utility and limitations of laser capture microdissection/RNA-seq and SLAM-ITseq in the Introduction (third paragraph).

> 3\) In Figure 3C, it was noted that only 53 to 74% of the aligned reads were mapped to the human genome after IP in 5-FC treated mice. Does it mean that 26 to 47% of the reads are derived from contaminating mouse reads? What does this mean for the efficacy of the staining and IP purification? Can one then trust that all the human reads correspond to stained RNA of actively transcribed genes with such a noisy technique? How good is the qPCR to assess the signal-to-noise ratio of the technique (for example Figure 3B) and why is there such a discrepancy between Figure 3B and 3C results?

The remaining 26 to 47% of the reads in Figure 3C are indeed from contaminating mouse reads. The primary purpose of Flura-seq is to enrich RNAs from the cells of interest. We would like to clarify that in the experiment described in Figure 3C, the mRNAs from human cells were enriched from less than 1% in the input sample (0.003 to 0.08% of total cell numbers; Figure 3---figure supplement 1D, E) to 53 to 74%. Bioinformatic filtering based on the enrichment relative to input can remove all the reads coming from mouse sequences (Figure 3D) without significant effect on human transcript levels (Figure 3D). Such filtering is commonly used with other in situtranscriptomics methods involving immunoprecipitation or other pull down methods (Gay et al., Genes & Development 2013; Doyle et al., Cell 2008).

In Figure 3B, the signal-to-noise ratio was calculated by obtaining a ratio of the enrichment of human transcript relative to mouse transcripts that is normalized to their corresponding inputs. The data in Figure 3C is not normalized to the corresponding inputs. The normalization likely increased the ratio by 1,000 to 10,000 in Figure 3B, hence there is no discrepancy between Figure 3C and 3D. To avoid confusion, we have changed "signal-to-noise ratio" to "relative fold enrichment" throughout the manuscript including in Figure 3B, and we have clearly stated the normalization to input in the figure legends where applicable.

> 4\) In Figure 4D, it was claimed that lung micrometastases have the highest content of unique transcriptional activity. However, what is lacking is an objective quantification of this uniqueness. This result is the reason why the remainder of the paper focuses on the specificity of the lung versus brain metastases and electron transport chain (ETC)/antioxidant gene expression levels, so this should be more convincing.

We have included a new panel to address this point (Figure 5---figure supplement 1A). We found 1528 genes upregulated only in lung micrometastases, versus 374 genes in brain micrometastases and 834 genes were commonly upregulated in both tissues compared to mammary tumor. Likewise, 1406 genes were downregulated only in lung micrometastases, versus 275 genes in brain micrometastases and 857 genes commonly downregulated in both tissues compared to mammary tumor. We hope this more clearly presents the rationale for focusing on lung versus brain metastases.

> 5\) Please comment on whether the main findings could be explained by the higher oxygen levels in the lung tissue compared to the brain and mammary fat pad. It is well known that high oxygen can lead to high levels of oxidative stress. This seems to be confirmed by the basal 4-HNE, GPX1 and NRF2 stainings in normal lung tissue, which are equally high as in the lung metastases and higher than in normal brain tissue (Figure 5C, E, F). Finally, in the comparison of in vitro cultures for example, the high oxygen levels could also be responsible for the loss of differences in the transcriptional profiles of ex vivo cultures from different organs (Figure 4B).

It is possible that the higher oxygen concentration in lung is at least partly responsible for higher oxidative stress and the counteracting antioxidative response observed in lung micrometastases. This further emphasizes the value of Flura-seq to capture a difference that is present only in an intact tissue microenvironment. However, we cannot eliminate other microenvironmental factors in the lung as possible contributors to this transcriptional feature. We have addressed this point in the Discussion (subsection "Flura-seq as an in situ transcriptomic technique with broad biological applications", second paragraph). It is possible that loss of differences in the transcriptional profiles of ex vivo cultures from different organs are due to high oxygen concentration in the culture condition.

> 6\) In co-culture experiments to assess the sensitivity of Flura-seq (Figure 1F), could the authors comment on why there isn\'t higher signal of human housekeeping genes in the samples when there are 10-fold more human cells?

In Figure 1F, the signal-to-noise ratio was normalized to the corresponding inputs, hence the ratio remained constant between 0.1 and 0.01% human cells as the input increased with immunoprecipitated RNAs. To clarify this, we have plotted the inputs and IP separately in the new Figure 1F which shows the result as expected.

> 7\) Many of the RNAs downregulated in TGFb control samples are also reduced in the Flura-seq samples, which seems surprising given the short 30 minute 5-FC labeling period. Was the signal for these genes low relative to the control samples, as expected? To assess this, it would be helpful to see the normalized count values for each condition in the supplemental tables (not just fold-change). Also, are there differentially expressed transcripts identified by Flura-seq that are not found in the control samples? Are they known TGF-b targets? Potential false-positives?

A closer analysis revealed that more than 90% of the repressed genes have higher reads in the Flura-seq samples compared to the control samples whereas the fold change is slightly lower in the Flura-seq samples (Supplementary file 2).This suggests that TGF-β repressed genes are regulated at the transcriptional level. This is consistent with previous reports from our lab and others that SMADs bind to the *MYC* cis-regulatory elements to repress transcription (Chen et al. Cell 2002; Frederick et al. MCB 2004).

In the revised manuscript, we have included normalized count values for all the differentially expressed genes identified in control samples by RNA-seq or Flura-seq samples in Supplementary file 2. Indeed, 575 genes were found to be differentially expressed by more than 2-fold upon TGF-β treatment by Flura-seq compared to 176 genes by RNA-seq. A majority of the genes identified only by Flura-seq show expression in the same direction in the control samples, although less than 2-fold. We have added a new figure panel (new Figure 2C) to illustrate that Flura-seq shows higher fold-change for TGF-β-induced genes, and genes that are identified only by Flura-seq are also induced in the control samples, albeit less than two-fold.

The genes identified to be induced by TGF-β only in Flura-seq are likely bona fide TGF-β target genes. To test if some of the genes in the list score upon longer TGF-β treatment, we compared the genes identified by Flura-seq to a published data set identifying TGF-β induced genes after 6 h of TGF-β treatment in MDA231 cells (Tufegdzic Vidakovic et al., Cell Reports 2015). Indeed, we found 83 of the genes were identified to be induced 6 h after TGF-β treatment (Supplementary file 2).

> 8\) Please clarify or reference how the 24 genes for the NRF2 signature were selected.

We generated a custom NRF2 signature by using NRF2 ChIP-seq data curated by Cistrome Database. We chose ChIP-seq samples of HeLa cells, which passed all the quality controls defined by the Cistrome Database (sequence quality, mapping quality, library complexity, ChIP enrichment, signal to noise ratio, regulatory regions). The 24-gene signature was obtained by overlapping the top 100 putative targets in duplicated ChIP-seq samples, which were curated by Cistrome Database. We have cited the paper that reported the ChIP-seq data and described how the target genes were selected in the title of Supplementary file 4, and added more details in the Results section (subsection "Mitochondrial Complex I expression and oxidative stress in lung micrometastatic cells", last paragraph).

> 9\) Please ensure that statistical significance of the results is addressed throughout, including in Figure 1F (where the SD is large), 2C, and 3B-C.

We have added the statistical significance in all the relevant figure panels.
